Previous 10 | Next 10 |
Are These The Best Biotech Stocks To Buy Right Now? One of the hottest investment themes in the stock market this year centered around biotech stocks . If you combine the words “biotech” and “small-cap” together, that could be a great recipe for b...
Abivertinib, one of Sorrento Therapeutics ' (NASDAQ: SRNE) COVID-19 drug candidates, will be entering phase 2 testing in Brazil. This follows approval granted on Wednesday by the National Health Surveillance Agency (ANVISA), the country's healthcare regulator, which has cleared the ...
This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers. We analyze key trends and...
Sorrento's ([[SRNE]] -13.2%) stock shows weakness, as investors appear to be disappointed at the company's COVID-19 pipeline and R&D update yesterday, as some shareholders seemingly had high hopes on announcement of groundbreaking news, at this highly anticipated event.While Sorrento...
Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...
Sorrento Therapeutics (NASDAQ: SRNE) , a clinical-stage biotech with an extensive COVID-19 product pipeline, is having a rough day today. The biotech's stock is down by a noteworthy 14% as of 10:54 a.m. EDT Wednesday. The culprit? Investors appear to be disappointed at Sorrento'...
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both geographies SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento The...
Gainers: Interpace Biosciences (IDXG) +42%, AnaptysBio (ANAB) +32%, Replimune Group (REPL) +31%, Allscripts Healthcare Solutions (MDRX) +29%, OncoCyte (OCX) +19%.Losers: Cyclerion Therapeutics (CYCN) -47%, Enzo Biochem (ENZ) -17%, So...
Cyclerion Therapeutics (CYCN) -41% after Phase 2 STRONG-SCD study results in patients with Sickle Cell Disease.Sorrento Therapeutics (SRNE) -12%.Aethlon Medical (AEMD) -11%.Enzo Biochem ENZ -10% on FQ4 earnings results.Auris Medical Holding (EARS) -10%.SOS ...
The U.S. Patent Office has awarded Sorrento Therapeutics (SRNE) patents for 1) Antibody therapeutics that bind CD38, and 2) Disulfide bridging conjugates.Shares are up 5.5% thirty minutes ahead of the close. For further details see: Sorrento Therapeutics awarded anti...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Fuse Medical Inc (FZMD) is expected to report for Q1 2024 PhoneX Holdings Inc (PXHI) is expected to report for Q1 2024 Avalon GloboCare Corp. (ALBT) is expected to report for Q1 2024 Ricoh Company Ltd ADR (RICOY) is expected to report for Q4 2024 Amplitech Group Inc. (AMPG) is exp...
Inpixon (INPXV) is expected to report for Q1 2024 Siebert Financial Corp. (SIEB) is expected to report for Q1 2024 Greenwave Technology Solutions Inc. (GWAV) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q1 2024 Gelesis Holdings, Inc. (...
Sorrento Therapeutics Inc. (SRNE) is expected to report for Q1 2023